Actinium Pharmaceuticals (NYSE:ATNM) traded higher on Tuesday as H.C. Wainwright highlighted its buyout potential after its ...

Actinium is a clinical-stage biopharmaceutical company that has devised an innovative strategy to overcome these hurdles. The company is leveraging its Antibody Warhead Enabling (AWE) technology ...

Actinium Pharmaceuticals Stock Down 4.9 % Shares of ATNM opened at $1.17 on Friday. The stock has a market capitalization of $36.50 million, a P/E ratio of -0.84 and a beta of 0.13. The firm has a ...

At the forefront of this development is Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing ARCs. It uses use internal radiation to fight cancer, by linking a ...